PACB vs. NAUT, AKYA, HBIO, QTRX, SEER, BNGO, AXDX, CTKB, LAB, and EYPT
Should you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include Nautilus Biotechnology (NAUT), Akoya Biosciences (AKYA), Harvard Bioscience (HBIO), Quanterix (QTRX), Seer (SEER), Bionano Genomics (BNGO), Accelerate Diagnostics (AXDX), Cytek Biosciences (CTKB), Standard BioTools (LAB), and EyePoint Pharmaceuticals (EYPT).
Nautilus Biotechnology (NASDAQ:NAUT) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.
Nautilus Biotechnology has higher earnings, but lower revenue than Pacific Biosciences of California. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
Pacific Biosciences of California received 442 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 67.73% of users gave Pacific Biosciences of California an outperform vote while only 16.67% of users gave Nautilus Biotechnology an outperform vote.
In the previous week, Pacific Biosciences of California had 4 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 6 mentions for Pacific Biosciences of California and 2 mentions for Nautilus Biotechnology. Pacific Biosciences of California's average media sentiment score of 0.00 beat Nautilus Biotechnology's score of -0.03 indicating that Nautilus Biotechnology is being referred to more favorably in the media.
Nautilus Biotechnology has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.
50.7% of Nautilus Biotechnology shares are held by institutional investors. 42.5% of Nautilus Biotechnology shares are held by insiders. Comparatively, 1.9% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Nautilus Biotechnology has a net margin of 0.00% compared to Nautilus Biotechnology's net margin of -152.97%. Pacific Biosciences of California's return on equity of -22.42% beat Nautilus Biotechnology's return on equity.
Nautilus Biotechnology presently has a consensus price target of $6.00, suggesting a potential upside of 140.96%. Pacific Biosciences of California has a consensus price target of $7.77, suggesting a potential upside of 428.76%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Nautilus Biotechnology.
Summary
Pacific Biosciences of California beats Nautilus Biotechnology on 10 of the 17 factors compared between the two stocks.
Get Pacific Biosciences of California News Delivered to You Automatically
Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacific Biosciences of California Competitors List
Related Companies and Tools
